NEUROCRINE BIOSCIENCES INC Marketable Securities (Non-Current)
NEUROCRINE BIOSCIENCES INC (NBIX) had Marketable Securities (Non-Current) of $299.40 million as of 2022-12-31, per its 10-K filed 2023-02-09.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent › Long-Term Investments
us-gaap:MarketableSecuritiesNoncurrent · last filed 2023-02-09
- 2022-12-31: Marketable Securities, Noncurrent $299.40M.
- 2021-12-31: Marketable Securities, Noncurrent $560.70M.
- 2020-12-31: Marketable Securities, Noncurrent $227.10M.
- 2019-12-31: Marketable Securities, Noncurrent $299.70M; Marketable Securities, Noncurrent as first filed $299.65M.
| Period end | Marketable Securities, Noncurrent | Marketable Securities, Noncurrent as first filed |
|---|---|---|
| 2022-12-31 | $299.40M 10-K · filed 2023-02-09 | |
| 2021-12-31 | $560.70M 10-K · filed 2023-02-09 | |
| 2020-12-31 | $227.10M 10-K · filed 2022-02-11 | |
| 2019-12-31 | $299.70M 10-K · filed 2021-02-05 | $299.65M 10-K · filed 2020-02-07 |
| 2018-12-31 | $216.03M 10-K · filed 2020-02-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |